---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002595"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:20:50.930080+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus swings to FY 2024 net income of $28.5M; UDENYCA divestiture on track

## Summary
- FY 2024 net income $28.5M ($0.25 diluted EPS) vs net loss $237.9M in FY 2023; revenue $267M, +4%.
- UDENYCA net revenue $206M (+62% YoY); LOQTORZI Q4 revenue $7.5M, +29% QoQ.
- Non-GAAP net loss $86.3M ($0.75 loss per share) improved from $186.2M in FY 2023.
- UDENYCA divestiture up to $558.4M; shareholder vote March 11, expected close late Q1/early Q2 2025.
- Post-divestiture projected cash ~$250M, cash runway >2 years; headcount reduction ~30%.

## SEC filing metadata
- accession: 0001558370-25-002595
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025002595/0001558370-25-002595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025002595/chrs-20250310x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002595
- JSON: https://secwatch.observer/filing/0001558370-25-002595.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.